{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:04:34Z","timestamp":1770833074048,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T00:00:00Z","timestamp":1451347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite increasing drug treatment options for metastatic castration\u2010resistant prostate cancer (<jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content>) patients, real\u2010world treatment data are lacking. We conducted retrospective analyses of commercial claims and electronic medical record (<jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content>) databases to understand how treatment patterns for <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content> have changed in a <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>\u2010based real\u2010world population. Truven Health Analytics MarketScan<jats:sup>\u00ae<\/jats:sup> (2000\u20132013) and <jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content> (2004\u20132013) databases were used to identify patients with an index prostate cancer diagnosis (<jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\u20109 codes 185X or 233.4X) and prescription claims for an <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content> drug (mitoxantrone, estramustine, docetaxel, sipuleucel\u2010T, cabazitaxel, abiraterone acetate, enzalutamide, or radium\u2010223). Regimen analyses for first line of therapy (<jats:styled-content style=\"fixed-case\">LOT<\/jats:styled-content>1), second line of therapy, and beyond were performed among cohorts based on year of first <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content> drug usage. <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content> drug usage and treatment duration were compared across cohorts and age groups within each cohort. The commercial claims cohort yielded 3437 evaluable patients. Most men (91%) commencing <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content> treatment had docetaxel as <jats:styled-content style=\"fixed-case\">LOT<\/jats:styled-content>1 in 2010; this number had declined to 15% in 2013. In 2013, 67% and 9% of patients used abiraterone acetate and enzalutamide, respectively, as <jats:styled-content style=\"fixed-case\">LOT<\/jats:styled-content>1. Among both commercial claims and <jats:styled-content style=\"fixed-case\">EMR<\/jats:styled-content> cohorts, treatment pattern changes were most pronounced in men aged &gt;80 years, and median treatment duration for some <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content> drugs was shorter than expected based on available clinical trial information. These results demonstrate a shift in <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content> treatments during the past 5 years, with greater use of newer noncytotoxic treatments than docetaxel. These real\u2010world data aid in understanding the changing role of chemotherapy in the management of <jats:styled-content style=\"fixed-case\">mCRPC<\/jats:styled-content>.<\/jats:p>","DOI":"10.1002\/cam4.576","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T07:58:39Z","timestamp":1451375919000},"page":"182-191","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Treatment evolution for metastatic castration\u2010resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real\u2010world data"],"prefix":"10.1002","volume":"5","author":[{"given":"Thomas W.","family":"Flaig","sequence":"first","affiliation":[{"name":"University of Colorado Cancer Center Medical Oncology  Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi C.","family":"Potluri","sequence":"additional","affiliation":[{"name":"Smart Analyst Inc.  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Ng","sequence":"additional","affiliation":[{"name":"Janssen Global Services Global Medical Affairs  Raritan New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary B.","family":"Todd","sequence":"additional","affiliation":[{"name":"Janssen Global Services Global Medical Affairs  Raritan New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maneesha","family":"Mehra","sequence":"additional","affiliation":[{"name":"Janssen Global Services Global Market Access Analytics  Raritan New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1742-1241.1985.tb07781.x","article-title":"Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate","volume":"39","author":"Garnick M. B.","year":"1985","journal-title":"Br. J. Clin. Pract."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.09.005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00034-0"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1756"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2011.04.014"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70018-X"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.4149"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70184-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.005"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0249"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1168175"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2013.770164"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.056"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-011-0160-6"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.09.005"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.12.004"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2519\/jospt.2003.33.4.163"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915050-00001"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_7_31_1","unstructured":"National Comprehensive Cancer Network.2016.NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline\u00ae): Prostate Cancer: Version 1. National Comprehensive Cancer Network Web site 2015 November 10; Available atwww.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. (accessed 30 November 2015)."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.576","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.576","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:25:23Z","timestamp":1696605923000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,29]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1002\/cam4.576"],"URL":"https:\/\/doi.org\/10.1002\/cam4.576","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,29]]},"assertion":[{"value":"2015-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}